Your browser doesn't support javascript.
loading
Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant.
Francica, Joseph R; Lynn, Geoffrey M; Laga, Richard; Joyce, M Gordon; Ruckwardt, Tracy J; Morabito, Kaitlyn M; Chen, Man; Chaudhuri, Rajoshi; Zhang, Baoshan; Sastry, Mallika; Druz, Aliaksandr; Ko, Kiyoon; Choe, Misook; Pechar, Michal; Georgiev, Ivelin S; Kueltzo, Lisa A; Seymour, Leonard W; Mascola, John R; Kwong, Peter D; Graham, Barney S; Seder, Robert A.
Afiliación
  • Francica JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Lynn GM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Laga R; Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic , 162 06 Prague, Czech Republic.
  • Joyce MG; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Ruckwardt TJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Morabito KM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Chen M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Chaudhuri R; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg, Maryland 20878, United States.
  • Zhang B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Sastry M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Druz A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Ko K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Choe M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Pechar M; Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic , 162 06 Prague, Czech Republic.
  • Georgiev IS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Kueltzo LA; Vaccine Production Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg, Maryland 20878, United States.
  • Seymour LW; Department of Oncology, University of Oxford , Oxford OX3 7DQ, U.K.
  • Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
  • Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland 20892, United States.
Bioconjug Chem ; 27(10): 2372-2385, 2016 10 19.
Article en En | MEDLINE | ID: mdl-27583777
ABSTRACT
Structure-based vaccine design has been used to develop immunogens that display conserved neutralization sites on pathogens such as HIV-1, respiratory syncytial virus (RSV), and influenza. Improving the immunogenicity of these designed immunogens with adjuvants will require formulations that do not alter protein antigenicity. Here, we show that nanoparticle-forming thermoresponsive polymers (TRP) allow for co-delivery of RSV fusion (F) protein trimers with Toll-like receptor 7 and 8 agonists (TLR-7/8a) to enhance protective immunity. Although primary amine conjugation of TLR-7/8a to F trimers severely disrupted the recognition of critical neutralizing epitopes, F trimers site-selectively coupled to TRP nanoparticles retained appropriate antigenicity and elicited high titers of prefusion-specific, TH1 isotype anti-RSV F antibodies following vaccination. Moreover, coupling F trimers to TRP delivering TLR-7/8a resulted in ∼3-fold higher binding and neutralizing antibody titers than soluble F trimers admixed with TLR-7/8a and conferred protection from intranasal RSV challenge. Overall, these data show that TRP nanoparticles may provide a broadly applicable platform for eliciting neutralizing antibodies to structure-dependent epitopes on RSV, influenza, HIV-1, or other pathogens.
Asunto(s)
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Polímeros / Proteínas Virales de Fusión / Adyuvantes Inmunológicos / Vacunas contra Virus Sincitial Respiratorio / Nanopartículas Límite: Animals Idioma: En Revista: Bioconjug Chem Asunto de la revista: BIOQUIMICA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Polímeros / Proteínas Virales de Fusión / Adyuvantes Inmunológicos / Vacunas contra Virus Sincitial Respiratorio / Nanopartículas Límite: Animals Idioma: En Revista: Bioconjug Chem Asunto de la revista: BIOQUIMICA Año: 2016 Tipo del documento: Article País de afiliación: Estados Unidos